000520.KS
Samil Pharmaceutical Co.,Ltd
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 7,690.00
−1.16%Year over year
Reported trailing growth
- Revenue
- -4.5%
- EBITDA
- —
- EBIT
- —
- EPS
- -84.5%
- Free cash flow
- +39.6%
- Operating cash flow
- +99.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +5.4%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026